These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37961353)

  • 21. Templated Aggregation of TAR DNA-binding Protein of 43 kDa (TDP-43) by Seeding with TDP-43 Peptide Fibrils.
    Shimonaka S; Nonaka T; Suzuki G; Hisanaga S; Hasegawa M
    J Biol Chem; 2016 Apr; 291(17):8896-907. PubMed ID: 26887947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Computationally Designed Molecules Modulate ALS-Related Amyloidogenic TDP-43
    Liu X; Duan S; Jin Y; Walker E; Tsao M; Jang JH; Chen Z; Singh AK; Cantrell KL; Ingolfsson HI; Buratto SK; Bowers MT
    ACS Chem Neurosci; 2023 Dec; 14(24):4395-4408. PubMed ID: 38050862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An
    Cascella R; Banchelli M; Abolghasem Ghadami S; Ami D; Gagliani MC; Bigi A; Staderini T; Tampellini D; Cortese K; Cecchi C; Natalello A; Adibi H; Matteini P; Chiti F
    Ann Med; 2023 Dec; 55(1):72-88. PubMed ID: 36495262
    [No Abstract]   [Full Text] [Related]  

  • 24. Point mutations in the N-terminal domain of transactive response DNA-binding protein 43 kDa (TDP-43) compromise its stability, dimerization, and functions.
    Mompeán M; Romano V; Pantoja-Uceda D; Stuani C; Baralle FE; Buratti E; Laurents DV
    J Biol Chem; 2017 Jul; 292(28):11992-12006. PubMed ID: 28566288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. S-nitrosylated TDP-43 triggers aggregation, cell-to-cell spread, and neurotoxicity in hiPSCs and in vivo models of ALS/FTD.
    Pirie E; Oh CK; Zhang X; Han X; Cieplak P; Scott HR; Deal AK; Ghatak S; Martinez FJ; Yeo GW; Yates JR; Nakamura T; Lipton SA
    Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33692125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of liquid-liquid phase separation in aggregation of the TDP-43 low-complexity domain.
    Babinchak WM; Haider R; Dumm BK; Sarkar P; Surewicz K; Choi JK; Surewicz WK
    J Biol Chem; 2019 Apr; 294(16):6306-6317. PubMed ID: 30814253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TDP-43 regulates the alternative splicing of hnRNP A1 to yield an aggregation-prone variant in amyotrophic lateral sclerosis.
    Deshaies JE; Shkreta L; Moszczynski AJ; Sidibé H; Semmler S; Fouillen A; Bennett ER; Bekenstein U; Destroismaisons L; Toutant J; Delmotte Q; Volkening K; Stabile S; Aulas A; Khalfallah Y; Soreq H; Nanci A; Strong MJ; Chabot B; Vande Velde C
    Brain; 2018 May; 141(5):1320-1333. PubMed ID: 29562314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The amyloidogenicity of a C-terminal region of TDP-43 implicated in Amyotrophic Lateral Sclerosis can be affected by anions, acetylation and homodimerization.
    Prasad A; Sivalingam V; Bharathi V; Girdhar A; Patel BK
    Biochimie; 2018 Jul; 150():76-87. PubMed ID: 29751083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SUMOylation Regulates TDP-43 Splicing Activity and Nucleocytoplasmic Distribution.
    Maraschi A; Gumina V; Dragotto J; Colombrita C; Mompeán M; Buratti E; Silani V; Feligioni M; Ratti A
    Mol Neurobiol; 2021 Nov; 58(11):5682-5702. PubMed ID: 34390468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between helix stability and binding affinities: molecular dynamics simulations of Bfl-1/A1-binding pro-apoptotic BH3 peptide helices in explicit solvent.
    Modi V; Lama D; Sankararamakrishnan R
    J Biomol Struct Dyn; 2013; 31(1):65-77. PubMed ID: 22803956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ALS-Causing Mutations Significantly Perturb the Self-Assembly and Interaction with Nucleic Acid of the Intrinsically Disordered Prion-Like Domain of TDP-43.
    Lim L; Wei Y; Lu Y; Song J
    PLoS Biol; 2016 Jan; 14(1):e1002338. PubMed ID: 26735904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TAR DNA-binding protein of 43 kDa (TDP-43) and amyotrophic lateral sclerosis (ALS): a promising therapeutic target.
    Ojaimi YA; Dangoumau A; Alarcan H; Hergesheimer R; Vourc'h P; Corcia P; Lanznaster D; Blasco H
    Expert Opin Ther Targets; 2022 Jun; 26(6):575-592. PubMed ID: 35652285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis.
    Prasad A; Bharathi V; Sivalingam V; Girdhar A; Patel BK
    Front Mol Neurosci; 2019; 12():25. PubMed ID: 30837838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD.
    Hayes LR; Kalab P
    Neurotherapeutics; 2022 Jul; 19(4):1061-1084. PubMed ID: 35790708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD.
    Kumar S; Phaneuf D; Cordeau P; Boutej H; Kriz J; Julien JP
    Mol Neurodegener; 2021 Jan; 16(1):1. PubMed ID: 33413517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Dissection of TDP-43 as a Leading Cause of ALS/FTLD.
    Tamaki Y; Urushitani M
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ALS Mutations Disrupt Phase Separation Mediated by α-Helical Structure in the TDP-43 Low-Complexity C-Terminal Domain.
    Conicella AE; Zerze GH; Mittal J; Fawzi NL
    Structure; 2016 Sep; 24(9):1537-49. PubMed ID: 27545621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TDP-43 dysregulation of polyadenylation site selection is a defining feature of RNA misprocessing in ALS/FTD and related disorders.
    Arnold FJ; Cui Y; Michels S; Colwin MR; Stockford C; Ye W; Tam OH; Menon S; Situ WG; Ehsani KCK; Howard S; Hammell MG; Li W; La Spada AR
    bioRxiv; 2024 Jan; ():. PubMed ID: 38328178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular mechanisms linking loss of TDP-43 function to amyotrophic lateral sclerosis/frontotemporal dementia-related genes.
    Koike Y
    Neurosci Res; 2024 May; ():. PubMed ID: 38723906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TDP-43 is a ubiquitylation substrate of the SCF
    Rayner SL; Yang S; Farrawell NE; Jagaraj CJ; Cheng F; Davidson JM; Luu L; Redondo AG; Rábano A; Borrego-Hernández D; Atkin JD; Morsch M; Blair IP; Yerbury JJ; Chung R; Lee A
    Neurobiol Dis; 2022 Jun; 167():105673. PubMed ID: 35231559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.